07:00 , Jul 25, 2016 |  BioCentury  |  Strategy

Paving the way

Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc .'s Humira adalimumab and...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

BIOCND Inc., Genor Biopharma deal

Genor granted BIOCND development rights to two mAbs. Genor granted BIOCND rights to GB232 , an adalimumab biosimilar, in South, Southeast and Northeast Asia (except Greater China) and Russia. It also granted BIOCND rights to...